Targeting mTOR (mammalian target of rapamycin) is an effective approach in the treatment of advanced RCC (renal cell carcinoma). Rapamycin-like drugs (rapalogues) have shown clinical activities and have been approved for the treatment of RCC. Recently, with the development of ATP-competitive inhibitors of mTOR, therapies targeting mTOR have entered a new era. Here, we discuss the biological relevance of blocking mTOR in RCC and review the mechanisms of action of rapalogues in RCC. We also advance some perspectives on the use of ATP-competitive inhibitors of mTOR in RCC.
ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
Didier Roulin, Nicolas Demartines, Olivier Dormond; ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma. Biochem Soc Trans 1 April 2011; 39 (2): 492–494. doi: https://doi.org/10.1042/BST0390492
Download citation file: